Response-Based Chemotherapy to treat newly diagnosed Acute Myeloid Leukemia /Myelodysplastic Syndrome patients with Down syndrome
Response-based chemotherapy separates patients into different risk groups according to how they respond to the first course of treatment
Acute Myeloid Leukemia Down Syndrome Myelodysplastic Syndrome Myeloid Leukemia Associated With Down Syndrome Myeloproliferative Neoplasm Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Preleukemia Myelodysplastic Syndromes Myeloproliferative Disorders Syndrome Cytarabine Etoposide Podophyllotoxin Daunorubicin Mitoxantrone Etoposide phosphate Asparaginase Mercaptopurine Thioguanine 2-Aminopurine Asparaginase Erwinia chrysanthemi Daunorubicin Hydrochloride Laboratory Biomarker Analysis Mitoxantrone Hydrochloride
Lead Scientists at UC Health
- Carla B. Golden (ucsf)
Professor, Pediatrics. Authored (or co-authored) 6 research publications.
- Marcio H. Malogolowkin (ucdavis)
Professor, Pediatrics. Authored (or co-authored) 94 research publications.
- Benjamin J. Huang (ucsf)
- Eduard H. Panosyan (ucla)
HS Associate Clinical Professor, Pediatrics. Authored (or co-authored) 24 research publications.
- accepting new patients
- Start Date
- Children's Oncology Group
- Phase 3
- Study Type
- Last Updated